Table 3.
Acute and preventive medication prescription trends among persistent (≥ 6 months) patients with a defined dose (n = 746)
| Number of prescriptions/month | |||
|---|---|---|---|
| Baseline | Follow-up | P valuea | |
| Acute medication, mean (SD) | 1.89 (2.86) | 1.87 (2.65) | 0.816 |
| Triptans | 0.68 (1.12) | 0.76 (1.18) | 0.111 |
| Ergot alkaloids | 0.04 (0.41) | 0.04 (0.38) | 0.887 |
| NSAID analgesics | 0.39 (0.95) | 0.30 (0.78) | 0.010 |
| Opioid analgesics | 0.56 (2.06) | 0.49 (1.72) | 0.246 |
| Miscellaneous | 0.21 (0.73) | 0.28 (1.20) | 0.071 |
| Preventive nonspecific migraine medication, mean (SD) | 2.22 (2.62) | 2.14 (2.48) | 0.349 |
| Anticonvulsants/antiepileptics | 0.81 (1.36) | 0.82 (1.40) | 0.823 |
| Antihypertensive | 0.34 (0.82) | 0.41 (0.99) | 0.056 |
| Muscle relaxants | 0.31 (0.90) | 0.30 (0.81) | 0.820 |
| Antidepressants | 0.62 (1.21) | 0.48 (1.02) | 0.002 |
| Antihistamines | 0.01 (0.12) | 0.01 (0.12) | 0.655 |
| OnabotulinumtoxinA | 0.14 (0.52) | 0.12 (0.55) | 0.315 |
SD standard deviation, NSAID nonsteroidal anti-inflammatory drug
aP values calculated via paired t-test; bold, italicized P values indicate statistical significance